
Sun Pharma Advanced Research Company is a subsidiary of Sun Pharmaceutical Industries, a global pharmaceutical company. It was established in 2003 to focus on developing new and innovative treatments.
The company's mission is to discover and develop novel therapies that address unmet medical needs. This mission is reflected in its research and development efforts.
Sun Pharma Advanced Research Company has a strong pipeline of products in various stages of development. Its research focus areas include cardiovascular, metabolic, and central nervous system disorders.
Explore further: Advanced Measurement Approach
You might like: PARC (company)
Company Information
Sun Pharma Advanced Research Company Limited is a clinical-stage biopharmaceutical company founded in 2006. It's based in India and has operations internationally.
The company has a relatively small team of 316 employees.
Anilkumar Raghavan serves as the CEO of Sun Pharma Advanced Research.
The company's website is sparc.life.
Discover more: Wörwag Pharma
Shareholding and Ownership
Sun Pharma Advanced Research has a stable shareholding pattern, with promoters holding a consistent 65.67% stake as of June 2025.
The company's shareholding pattern remains unchanged from the previous quarter, indicating a stable ownership structure.
As of June 2025, the promoters hold 21,31,15,095 shares, which translates to 65.67% of the total shareholding.
The pledge percentage is a notable 0.00%, indicating that there are no pledged shares as of June 2025.
In contrast, the Foreign Institutional Investor (FII) stake has increased by 0.03% to 1.48% as of June 2025.
Domestic Institutional Investors (DII) have decreased their stake by 0.16% to 0.96% as of June 2025.
Mutual Funds have also decreased their stake by 0.07% to 0.94% as of June 2025.
The remaining 31.89% of the shareholding is held by Others, which has increased by 0.13% as of June 2025.
Here's a breakdown of the shareholding pattern as of June 2025:
Market Data
The current share price of Sun Pharma Advanced Research is ₹128.05. This is a significant drop from its 52 Week High of ₹241.00.
The stock has seen some volatility in the past year, with a 1 Year Change of -38.20%. This is a substantial decline, and it's essential to keep an eye on the market trends.
Here's a breakdown of the stock's performance over the past few years:
The stock's beta is 0.24, indicating a relatively stable investment. However, the 1 Month Change of -9.24% and 3 Month Change of -17.93% suggest some recent fluctuations.
Technical Analysis
Sun Pharma Advanced Research's technical analysis is a crucial aspect of understanding its performance. The company doesn't have any Buy/Sell Signals.
The stock has shown a 41% positive movement since 1st January 2005, but a 58% negative movement since the same date. Excluding global meltdowns and the Covid crisis, the stock's performance is still quite volatile.
Pivot levels and Average True Range (ATR) are essential tools for technical analysis. However, Sun Pharma Advanced Research's pivot levels and ATR are currently not available.
Here's a brief overview of the stock's performance:
The stock's price has been declining consistently over the past few years, with a negative performance in most timeframes.
Corporate Actions
Sun Pharma Advanced Research Company (SPARC) is a subsidiary of Sun Pharmaceutical Industries Ltd. that focuses on developing innovative products.
SPARC has a strong pipeline of products in various therapeutic areas, including dermatology and ophthalmology.
The company has a collaborative approach to research and development, partnering with other organizations to accelerate the development of new products.
A different take: Research and Development Expenditure Credit
SPARC has a significant presence in the US market, with a strong portfolio of generic and branded products.
The company's expertise in formulation development has enabled it to create complex products that meet the needs of patients.
SPARC has a robust quality control system in place to ensure the highest standards of quality in its products.
The company's research and development efforts are focused on creating innovative products that address unmet medical needs.
SPARC has a team of experienced researchers and scientists who work together to develop new products.
The company's commitment to quality and innovation has earned it a reputation as a trusted partner in the pharmaceutical industry.
For another approach, see: American Research and Development Corporation
Frequently Asked Questions
Why is Sun Pharma's advanced research share falling?
Sun Pharma's Advanced Research shares are falling due to the failure of a psoriasis drug in Phase 2 trials, casting uncertainty over the company's specialty drug pipeline. This setback has led to a 20% decline in share value.
What is the issue with Sun Pharma?
Sun Pharma has issued a recall of approximately 13,700 bottles due to cross-contamination risks, affecting a widely used epilepsy and nerve pain treatment. This recall highlights quality assurance lapses in the company's manufacturing process.
Featured Images: pexels.com


